NCT05706207 - A Study of HB0030 Injection in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions

Advanced Solid Tumor

Interventions

DRUG

HB0030 injection

0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

DRUG

HB0030 injection

40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance

Trial Locations (1)

RECRUITING

the First Affiliated Hospital of Bengbu Medical College, Bengbu